Skip to main content

244 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

  1. Thompson A, et al. Late onset neutropenia with clozapine. Can J Psychiatry 2004; 49:647–648.
  2. Bhanji NH, et al. Late-­onset agranulocytosis in a patient with schizophrenia after 17 months of clozapine treatment. J Clin Psychopharmacol 2003; 23:522–523.
  3. Sedky K, et al. Clozapine-­induced agranulocytosis after 11 years of treatment [Letter]. Am J Psychiatry 2005; 162:814.
  4. de Araujo CF, et  al. Delayed-­onset severe neutropenia associated with clozapine with successful rechallenge at lower dose. J Clin Psychopharmacol 2021; 41:77–79.
  5. Kang BJ, et al. Long-­term patient monitoring for clozapine-­induced agranulocytosis and neutropenia in Korea: when is it safe to discontinue CPMS? Hum Psychopharmacol 2006; 21:387–391.
  6. Panesar N, et al. Late onset neutropenia with clozapine. Aust N Z J Psychiatry 2011; 45:684.
  7. Tourian L, et  al. Late-­onset agranulocytosis in a patient treated with clozapine and lamotrigine. J Clin Psychopharmacol 2011; 31:665–667.
  8. Hawe R, et al. Response to clozapine-­induced microscopic colitis: a case report and review of the literature. J Clin Psychopharmacol 2008; 28:454–455.
  9. Shah V, et al. Clozapine-­induced ischaemic colitis. BMJ CaseRep 2013; 2013:bcr2012007933.
  10. Linsley KR, et al. Clozapine-­associated colitis: case report and review of the literature. J Clin Psychopharmacol 2012; 32:564–566.
  11. Baptista T. A fatal case of ischemic colitis during clozapine administration. Rev Bras Psiquiatr 2014; 36:358.
  12. Rodriguez-­Sosa JT, et al. Apropos of a case: relationship of ischemic colitis with clozapine. Actas Esp Psiquiatr 2014; 42:325–326.
  13. Osterman MT, et al. Clozapine-­induced acute gastrointestinal necrosis: a case report. J Med Case Rep 2017; 11:270.
  14. Holz K, et al. Clozapine associated with microscopic colitis in the setting of biopsy-­proven celiac disease. J Clin Psychopharmacol 2018; 38:150–152.
  15. Rask SM, et al. Clozapine-­related diarrhea and colitis: report of 4 cases. J Clin Psychopharmacol 2020; 40:293–296.
  16. Verdoux H, et al. Clinical determinants of fever in clozapine users and implications for treatment management: a narrative review. Schizophr Res 2019; 211:1–9.
  17. Peyriere H, et al. Antipsychotics-­induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. Pharmacoepidemiol Drug Saf 2009; 18:948–955.
  18. Centorrino F, et  al. Delirium during clozapine treatment: incidence and associated risk factors. Pharmacopsychiatry 2003; 36:156–160.
  19. Shankar BR. Clozapine-­induced delirium. J Neuropsychiatry Clin Neurosci 2008; 20:239–240.
  20. Khanra S, et al. An unusual case of delirium after restarting clozapine. Clin Psychopharmacol Neurosci 2016; 14:107–108.
  21. Gaertner HJ, et al. Side effects of clozapine. Psychopharmacology (Berl) 1989; 99 Suppl:S97–S100.
  22. Friedrich ME, et al. Incidence of drug-­induced delirium during treatment with antidepressants or antipsychotics: a drug surveillance report of German-­speaking countries between 1993 and 2016. Int J Neuropsychopharmacol 2022; 25:556–566.
  23. Hummer M, et al. Does eosinophilia predict clozapine induced neutropenia? Psychopharmacology 1996; 124:201–204.
  24. Ames D, et al. Predictive value of eosinophilia for neutropenia during clozapine treatment. J Clin Psychiatry 1996; 57:579–581.
  25. Wysokinski A, et al. Rapidly developing and self-­limiting eosinophilia associated with clozapine. Psychiatry Clin Neurosci 2015; 69:122.
  26. Aneja J, et  al. Eosinophilia induced by clozapine: a report of two cases and review of the literature. J Family Med Prim Care 2015; 4:127–129.
  27. Lally J, et al. Hepatitis, interstitial nephritis, and pancreatitis in association with clozapine treatment: a systematic review of case series and reports. J Clin Psychopharmacol 2018; 38:520–527.
  28. Marchel D, et al. Multiorgan eosinophilic infiltration after initiation of clozapine therapy: a case report. BMC Res Notes 2017; 10:316.
  29. Chatterton R. Eosinophilia after commencement of clozapine treatment. Aust N Z J Psychiatry 1997; 31:874–876.
  30. Chan SY, et al. Clozapine-­induced acute interstitial nephritis. Hong Kong Med J 2015; 21:372–374.
  31. Lally J, et al. Rechallenge following clozapine-­associated eosinophilia: a case report and literature review. J Clin Psychopharmacol 2019; 39:504–506.
  32. Karmacharya R, et al. Clozapine-­induced eosinophilic colitis [Letter]. Am J Psychiatry 2005; 162:1386–1387.
  33. de Filippis R, et  al. Antipsychotic-­related DRESS syndrome: analysis of individual case safety reports of the WHO Pharmacovigilance Database. Drug Saf 2024; 47:745–757.
  34. de Filippis R, et al. Unravelling cases of clozapine-­related drug reaction with eosinophilia and systemic symptoms (DRESS) in patients reported otherwise: a systematic review. J Psychopharmacol 2021; 35:1062–1073.
  35. McArdle PA, et al. Successful rechallenge with clozapine after treatment associated eosinophilia. Australas Psychiatry 2016; 24:365–367.
  36. Fabrazzo M, et al. Clozapine versus other antipsychotics during the first 18 weeks of treatment: a retrospective study on risk factor increase of blood dyscrasias. Psychiatry Res 2017; 256:275–282.
  37. Sanader B, et  al. Clozapine-­induced DRESS syndrome: a case series from the AMSP Multicenter Drug Safety Surveillance Project. Pharmacopsychiatry 2019; 52:156–159.
  38. Kerwin RW, et al. Heat stroke in schizophrenia during clozapine treatment: rapid recognition and management. J Psychopharmacol 2004; 18:121–123.
  39. Hoffmann MS, et al. Heat stroke during long-­term clozapine treatment: should we be concerned about hot weather? Trends Psychiatry Psychother 2016; 38:56–59.
  40. Erdogan A, et al. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med 2004; 34:83–89.

248 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 41. Macfarlane B, et al. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-­induced hepatotoxicity. Gastroenterology 1997; 112:1707–1709. 42. Chang A, et al. Clozapine-­induced fatal fulminant hepatic failure: a case report. Can J Gastroenterol 2009; 23:376–378. 43. Chaplin AC, et al. Re: Recent case report of clozapine-­induced acute hepatic failure. Can J Gastroenterol 2010; 24:739–740. 44. Wu Chou AI, et  al. Hepatotoxicity induced by clozapine: a case report and review of literature. Neuropsychiatr Dis Treat 2014; 10:1585–1587. 45. Kane JP, et al. Clozapine-­induced liver injury and pleural effusion. Ment Illn 2014; 6:5403. 46. Douros A, et al. Drug-­induced liver injury: results from the hospital-­based Berlin Case–Control Surveillance Study. Br J Clin Pharmacol 2015; 79:988–999. 47. Tucker P. Liver toxicity with clozapine. Aust N Z J Psychiatry 2013; 47:975–­976. 48. Fong SY, et al. Clozapine-­induced toxic hepatitis with skin rash. J Psychopharmacol 2005; 19:107. 49. Burk BG, et al. A case report of acute hypothermia during initial inpatient clozapine titration with review of current literature on clozapine-­ induced temperature dysregulations. BMC Psychiatry 2020; 20:290. 50. McLoughlin C, et al. Clozapine-­induced interstitial nephritis in a patient with schizoaffective disorder in the forensic setting: a case report and review of the literature. Ir J Psychol Med 2022; 39:106–111. 51. Vantipalli P, et al. Acute interstitial nephritis induced by clozapine. J Med Cases 2022; 13:322–329. 52. Can KC, et al. A very rare adverse effect of clozapine, clozapine-­induced interstitial lung disease: case report and literature review. Noro Psikiyatr Ars 2019; 56:313–315. 53. Torrico T, et al. Clozapine-­induced pneumonitis: a case report. Front Psychiatry 2020; 11:572102. 54. Sahib Din J, et al. Knee buckling as an atypical adverse effect of clozapine: a case report. Cureus 2024; 16:e55865. 55. Uzun Ö, et al. Knee buckling (negative myoclonus) associated with clozapine: reports on 3 cases. Clin Neuropharmacol 2020; 43:26–27. 56. Mu C, et al. Characteristics of eye disorders induced by atypical antipsychotics: a real-­world study from 2016 to 2022 based on Food and Drug Administration Adverse Event Reporting System. Front Psychiatry 2024; 15:1322939. 57. Borovik AM, et al. Ocular pigmentation associated with clozapine. Med J Aust 2009; 190:210–211. 58. Huttlin EA, et al. Periorbital edema associated with clozapine and gabapentins: a case report. J Clin Psychopharmacol 2020; 40:198–199. 59. Ceylan E, et al. The ocular surface side effects of an anti-­psychotic drug, clozapine. Cutan Ocul Toxicol 2016; 35:62–66. 60. Bergemann N, et al. Asymptomatic pancreatitis associated with clozapine. Pharmacopsychiatry 1999; 32:78–80. 61. Raja M, et al. A case of clozapine-­associated pancreatitis. Open Neuropsychopharmacol J 2011; 4:5–7. 62. Bayard JM, et al. Case report: acute pancreatitis induced by Clozapine. Acta Gastroenterol Belg 2005; 68:92–94. 63. Sani G, et al. Development of asymptomatic pancreatitis with paradoxically high serum clozapine levels in a patient with schizophrenia and the CYP1A2*1F/1F genotype. J Clin Psychopharmacol 2010; 30:737–739. 64. Wehmeier PM, et al. Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine. J Clin Psychopharmacol 2003; 23:102–103. 65. Garlipp P, et al. The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. J Psychopharmacol 2002; 16:399–400. 66. Gatto EM, et al. Clozapine and pancreatitis. Clin Neuropharmacol 1998; 21:203. 67. Martin A. Acute pancreatitis associated with clozapine use. Am J Psychiatry 1992; 149:714. 68. Yildiz MI, et  al. All in one: clozapine-­associated acute pancreatitis with multiple organ involvement. J Clin Psychopharmacol 2021; 41:214–216. 69. de Filippis R, et al. Clozapine-­associated pericarditis and pancreatitis in children and adolescents: a systematic literature review and pharmacovigilance study using the VigiBase database. Schizophr Res 2024; 268:118–130. 70. Cerulli TR. Clozapine-­associated pancreatitis. Harv Rev Psychiatry 1999; 7:61–63. 71. Huang YJ, et al. Recurrent pancreatitis without eosinophilia on clozapine rechallenge. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:1561–­1562. 72. Chengappa KN, et al. Recurrent pancreatitis on clozapine re-­challenge. J Psychopharmacol 1995; 9:381–382. 73. Frankenburg FR, et al. Eosinophilia, clozapine, and pancreatitis. Lancet 1992; 340:251. 74. Ratcliff K, et al. Clozapine rechallenge with recurrent pancreatitis. Prim Care Companion CNS Disord 2022; 24:22cr03237. 75. DeRemer CE, et al. Clozapine drug-­induced pancreatitis of intermediate latency of onset confirmed by de-­challenge and re-­challenge. Int J Clin Pharmacol Ther 2019; 57:37–40. 76. Immadisetty V, et al. A successful treatment strategy for clozapine-­induced parotid swelling: a clinical case and systematic review. Ther Adv Psychopharmacol 2012; 2:235–239. 77. Gouzien C, et al. [Clozapine-­induced parotitis: a case study]. Encephale 2014; 40:81–85. 78. Saguem BN, et al. Eosinophilia and parotitis occurring early in clozapine treatment. Int J Clin Pharm 2015; 37:992–995. 79. Vohra A. Clozapine-­induced recurrent and transient parotid gland swelling. Afr J Psychiatry (Johannesbg) 2013; 16:236, 238. 80. Kathirvel N, et al. Recurrent transient parotid gland swelling with clozapine therapy. Ir J Psychol Med 2014; 25:69–70. 81. Brodkin ES, et al. Treatment of clozapine-­induced parotid gland swelling. Am J Psychiatry 1996; 153:445. 82. Vasile JS, et al. Clozapine and the development of salivary gland swelling: a case study. J Clin Psychiatry 1995; 56:511–513. 83. Bhatti MA, et al. Clozapine-­induced pericarditis, pericardial tamponade, polyserositis, and rash. J Clin Psychiatry 2005; 66:1490–1491. 84. Boot E, et al. Pericardial and bilateral pleural effusion associated with clozapine treatment. Eur Psychiatry 2004; 19:65. 85. Murko A, et al. Clozapine and pericarditis with pericardial effusion. Am J Psychiatry 2002; 159:494. 86. Imon Paul MD, et al. Clozapine induced pericarditis: an overlooked adverse effect. Clin Schizophr Relat Psychoses 2014; 8:133–134. 87. Bath AS, et al. Pericardial effusion: rare adverse effect of clozapine. Cureus 2019; 11:e4890.

Schizophrenia and related psychoses CHAPTER 1 88. Johal HK, et al. Clozapine-­induced pericarditis: an ethical dilemma. BMJ Case Rep 2019; 12:e229872. 89. Sahyouni C, et al. Clozapine induced pericarditis: a case report. Psychiatry Res 2021; 305:114250. 90. Gilbreth N, et al. Clozapine-­induced pericardial effusion presenting with persistent tachycardia. Case Rep Med 2021; 2021:5523562. 91. Prisco V, et al. Brain natriuretic peptide as a biomarker of asymptomatic clozapine-­related heart dysfunction: a criterion for a more cautious administration. Clin Schizophr Relat Psychoses 2016; 12:185–188. 92. Crews MP, et al. Clozapine rechallenge following clozapine-­induced pericarditis. J Clin Psychiatry 2010; 71:959–961. 93. Sarathy K, et al. A successful re-­trial after clozapine myopericarditis. J R Coll Physicians Edinb 2017; 47:146–147. 94. Boscutti A, et al. Successful clozapine rechallenge after myopericarditis: a case report. Int Clin Psychopharmacol 2022; 37:179–181. 95. Nikvarz N, et al. Drug-­induced stuttering: a comprehensive literature review. World J Psychiatry 2022; 12:236–263. 96. Trenque T, et al. Drug induced stuttering: pharmacovigilance data. Expert Opin Drug Saf 2021; 20:373–378. 97. Duggal HS, et al. Clozapine-­induced stuttering and seizures. Am J Psychiatry 2002; 159:315. 98. Jagadheesan K, et al. Clozapine-­induced thrombocytopenia: a pilot study. Hong Kong J Psychiatry 2003; 13:12–15. 99. Mihaljevic-­Peles A, et al. Thrombocytopenia associated with clozapine and fluphenazine. Nord J Psychiatry 2001; 55:449–450. 100. Rudolf J, et al. Clozapine-­induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. J Neural Transm (Vienna) 1997; 104:1305–1311. 101. Assion HJ, et al. Lymphocytopenia and thrombocytopenia during treatment with risperidone or clozapine. Pharmacopsychiatry 1996; 29:227–228. 102. Lee J, et al. The effect of clozapine on hematological indices: a 1-­year follow-­up study. J Clin Psychopharmacol 2015; 35:510–516. 103. Grover S, et  al. Haematological side effects associated with clozapine: a retrospective study from India. Asian J Psychiatr 2020; 48:101906. 104. Kate N, et al. Clozapine associated thrombocytopenia. J Pharmacol Pharmacother 2013; 4:149–151. 105. Gonzales MF, et al. Evidence for immune etiology in clozapine-­induced thrombocytopenia of 40 months’ duration: a case report. CNS Spectr 2000; 5:17–18. 106. Hauseux PA, et al. Clozapine rechallenge after thrombocytopenia: a case report. Schizophr Res 2020; 222:477–479. 107. Thapaliya S, et al. Effective and safe use of intramuscular clozapine in a patient presenting with catatonia and thrombocytopenia. BMJ Case Rep 2024; 17:e260197. 108. Hampson ME. Clozapine-­induced thrombocytosis. Br J Psychiatry 2000; 176:400. 109. Warnock JK, et al. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol 2002; 3:629–636. 110. Wu BY, et al. Prevalence and associated factors of comorbid skin diseases in patients with schizophrenia: a clinical survey and national health database study. Gen Hosp Psychiatry 2014; 36:415–421. 111. Voulgari C, et al. Clozapine-­induced late agranulocytosis and severe neutropenia complicated with streptococcus pneumonia, venous thromboembolism, and allergic vasculitis in treatment-­resistant female psychosis. Case Rep Med 2015; 2015:703218. 112. Penaskovic K, et al. Clozapine-­induced allergic vasculitis [Letter]. Am J Psychiatry 2005; 162:1543–1542. 113. Mukherjee S, et al. Leukocytoclastic vasculitis secondary to clozapine. Indian J Psychiatry 2019; 61:94–96. 114. Fujimoto S, et al. Clozapine-­induced antineutrophil cytoplasmic antibody-­associated vasculitis: a case report. Mod Rheumatol Case Rep 2020; 4:70–73. 115. Wu MK, et al. The severe complication of Stevens–Johnson syndrome induced by long-­term clozapine treatment in a male schizophrenia patient: a case report. Neuropsychiatr Dis Treat 2015; 11:1039–1041. 116. Lai YW, et al. Pityriasis rosea-­like eruption associated with clozapine: a case report. Gen Hosp Psychiatry 2012; 34:703.e5–e7. 117. Bhatia MS, et al. Clozapine induced pityriasiform eruption. Indian J Dermatol 1997; 42:245–246. 118. Stanislav SW, et al. Papular rash and bilateral pleural effusion associated with clozapine. Ann Pharmacother 1999; 33:1008–1009. 119. Bosonnet S, et al. [Acute generalized exanthematic pustulosis after intake of clozapine (leponex). First case]. Ann Dermatol Venereol 1997; 124:547–548. 120. El Ouni Amami N, et al. Clozapine-­induced cholinergic urticaria: a case report. Ther Adv Psychopharmacol 2024; 14:20451253241241056. 121. Bunting A, et al. Clozapine and Sweet’s syndrome: case report. BJPsych Open 2023; 9:e166. 122. Kleinen JM, et  al. [Clozapine-­induced agranulocytosis and Sweet’s syndrome in a 74-­year-­old female patient: a case study]. Tijdschr Psychiatr 2008; 50:119–123. 123. de Filippis R, et al. Clozapine-­related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. Expert Rev Clin Pharmacol 2020; 13:875–883. 124. Chate S, et al. Pulmonary thromboembolism associated with clozapine. J Neuropsychiatry Clin Neurosci 2013; 25:E3–E6. 125. Yang TY, et al. Massive pulmonary embolism in a young patient on clozapine therapy. J Emerg Med 2004; 27:27–29. 126. Huang J, et  al. Association between antipsychotics and pulmonary embolism: a pharmacovigilance analysis. Expert Opin Drug Saf 2024; doi: 10.1080/14740338.2024.2396390. 127. Gami RK, et al. Pulmonary embolism and clozapine use: a case report and literature review. Psychosomatics 2017; 58:203–208. 128. Hagg S, et al. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf 2009; 8:537–­547. 129. De Fazio P, et al. Rare and very rare adverse effects of clozapine. Neuropsychiatr Dis Treat 2015; 11:1995–2003. 130. Sarvaiya N, et al. Clozapine-­associated pulmonary embolism: a high-­mortality, dose-­independent and early-­onset adverse effect. Am J Ther 2018; 25:e434–e438. 131. Pallares Vela E, et al. Clozapine-­related thromboembolic events. Cureus 2021; 13:e16883. 132. Robbins-­Welty GA, et  al. Pulmonary embolism during a retrial of low-­dose clozapine. Clin Psychopharmacol Neurosci 2022; 20:578–580.

250 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 133. Goh JG, et al. A case report of clozapine continuation after pulmonary embolism in the context of other risk factors for thromboembolism. Aust N Z J Psychiatry 2016; 50:1205–1206. 134. Munoli RN, et al. Clozapine-­induced recurrent pulmonary thromboembolism. J Neuropsychiatry Clin Neurosci 2013; 25:E50–E51. 135. Selten JP, et al. Clozapine and venous thromboembolism: further evidence. J Clin Psychiatry 2003; 64:609. 136. Manoubi SA, et al. Fatal pulmonary embolism in patients on antipsychotics: case series, systematic review and meta-­analysis. Asian J Psychiatr 2022; 73:103105. 137. Mouaffak F, et  al. Clozapine-­induced serositis: review of its clinical features, pathophysiology and management strategies. Clin Neuropharmacol 2009; 32:219–223. 138. Bonnet U, et al. Late-­onset polyserositis emerging during long-­term clozapine treatment and persisting after clozapine discontinuation: is clozapine really innocent? J Clin Psychopharmacol 2022; 42:106–107.

No comments to display

Back to top